Biotech Seen Returning To Outperformance Despite Political, Pricing Risks

UBS analyst Carter Gould started coverage of several biotech names with a Buy rating, saying he finds bullish signals amid the noise and expects the sector to return to outperformance, overcoming continued political and pricing risks.